You are here: Industry Insights > Pancreatic cancer

News List

Liposomal Irinotecan: A New Hope for The First-line Treatment of Metastatic Pancreatic Cancer YuZai
July 03, 2024
Pancreatic cancer, known as the king of cancer, was diagnosed with pancreatic ductal adenocarcinoma in approximately 496,000 people worldwide in 2020 and is the seventh leading cause of cancer-related deaths.
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology PharmaSources
April 17, 2024
Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE prnasia
November 24, 2021
Alphamab Oncology (stock code: 9966.HK) announced that the IND application for phase 3 registration study (KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine...
FDA Grants Pancreatic Cancer Treatment Orphan Drug Designation americanpharmaceuticalreview
July 29, 2021
XOMA Corporation announced NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. FDA.
Liquid Biopsy Exosomal miRNA Panel Predicts Recurrence Following Surgery for Pancreatic Cancer firstwordpharma
May 26, 2021
A liquid biopsy exosomal microRNA (miRNA) panel can accurately predict cancer recurrence following surgery for pancreatic ductal adenocarcinoma, according to a study presented at Digestive Disease Week (DDW) 2021.
Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy firstwordpharma
May 21, 2021
Cantargia AB today announced positive results from the ongoing CANFOUR trial investigating nadunolimab (CAN04) in combination with gemcitabine/nab-paclitaxel (Abraxane®) for first line treatment of patients with advanced pancreatic cancer (PDAC).
Pancreatic cancer market to reach $4.1 billion by 2029: GlobalData expresspharma
April 26, 2021
Growth in pancreatic cancer therapy market will be driven by the introduction of drugs with novel mechanisms of action, across several lines of therapies, which are poised to meet high unmet need in the US and 5EU.
FibroGenesis Reports Positive Data in Pancreatic, Breast Cancer Using Fibroblast-Based Immunotherapy americanpharmaceuticalreview
February 20, 2021
FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination americanpharmaceuticalreview
February 03, 2021
Agenus has entered into a clinical collaboration with Nelum to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line ...
V2ACT Therapeutics Announces IND for V2ACT Study for Pancreatic Cancer americanpharmaceuticalreview
January 05, 2021
V2ACT Therapeutics™ has obtained permission from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application and may proceed with the clinical investigation of V2ACT in a Phase 1/2a trial for the treatment of newly ...

Previous page 1 2 3 4 5 6 Next page